Jump to main content
Jump to site search

Issue 20, 2005
Previous Article Next Article

Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

Author affiliations

Abstract

Currently available non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are directed at the cyclooxygenase (COX) site, but not the peroxidase (POX) activity of prostaglandin H2 synthase (PGHS). They are thus unable to inhibit the free-radical induced tissue injury associated with PGHS peroxidase activity, which can occur independently of the COX site. A lead compound, anthranilic hydroxamic acid (AHA) was found to have significant PGHS-POX inhibitory activity (IC50 = 72 µM). To define the critical parameters for PGHS-POX inhibition, we investigated 29 AHA derivatives, synthesised from their acid precursors, using solid phase synthesis. In vitro analysis demonstrated a ten-fold improvement in inhibition with 3,5-diiodoanthranilic hydroxamic acid (IC50 = 7 µM).

Graphical abstract: Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

Back to tab navigation

Supplementary files

Publication details

The article was received on 20 Apr 2005, accepted on 02 Aug 2005 and first published on 08 Sep 2005


Article type: Paper
DOI: 10.1039/B505525C
Citation: Org. Biomol. Chem., 2005,3, 3678-3685
  •   Request permissions

    Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

    J. Lee, A. J. Chubb, E. Moman, B. M. McLoughlin, C. T. Sharkey, J. G. Kelly, K. B. Nolan, M. Devocelle and D. J. Fitzgerald, Org. Biomol. Chem., 2005, 3, 3678
    DOI: 10.1039/B505525C

Search articles by author

Spotlight

Advertisements